The renin-angiotensin system in the human eye

The circulating renin-angiotensin system (RAS) plays an important role in the control of electrolyte homeostasis and blood pressure. The rate limiting step in the RAS system is the kidney derived enzyme renin, an aspartyl protease, which cleaves its substrate angiotensinogen, a liver derived circulating α1-globulin in plasma, to form the decapeptide angiotensin I. Angiotensin I is then converted by the angiotensin converting enzyme (ACE) to the octapeptide angiotensin II, which stimulates release of aldosterone and constriction of blood vessels. Vasoconstriction has been demonstrated in feline retinal blood vessels exposed to angiotensin II, and angiotensin binding sites have been found in bovine and human retinal vessels.1,2

All of the RAS components are present in the circulating blood and in a number of peripheral tissues, including the human eye. Ophthalmic literature concerning the RAS started in 1977 with a study by Igc and coworkers4 on the detection of ACE activity in homogenates of the retina and since then the role of the RAS in the eye has been reported in about 30 publications. Enzyme activities of ACE have been reported further in aqueous humour, vitreous humour, tear fluid, retina, and ciliary body of different species including humans.5-13 In rat eyes the enzyme only has been found in the ciliary body but not in the retina.14 In dog saphenous vein very low ACE activity has been measured.15 The presence of angiotensin II has been demonstrated in human16,17 and feline18 vitreous and in pig retina and anterior uveal tract.19 Prorenin, the biosynthetic inactive precursor of renin, was detected in human ciliary body19 and vitreous humour20 at concentrations higher than in plasma.21,22 In all segments of bovine eyes the concentration was much too high to be explained by admixture of blood or leakage from the vascular system,23 suggesting a local production.

In the above mentioned studies the source of renin and ACE in the eye has not been determined with certainty as apart from local synthesis there is the possibility of selective uptake by the tissues. If the components of the RAS are synthesised locally in the eye, then the gene should be expressed in the ocular tissues. Using polymerase chain reaction (PCR) with renin specific primers and in situ hybridisation with a specific cDNA clone, Wallow et al.24 and Brandt et al.25 in 1994 showed that renin mRNA is present in iris, retinal tissue and neural retina, ciliary body, ciliary muscle, and tissue closely related to the outflow channels of the anterior chamber in the rat.

In this issue of the BJ O, Wagner et al. (p 159) reported their findings in human eyes, using the molecular biology technique of reverse transcription PCR for expression of all components of the RAS in individual eye samples and a RNase protection assay to detect renin-mRNA in pooled tissue samples. They confirmed gene expression of renin, as was found earlier in the rat,24,25 and also found expression of angiotensinogen and ACE in neural retina, retinal pigment epithelium, and choroid; however, no expression was observed in iris and ciliary body. The present study brings the subject closer to the explanation and possible therapy of some human ocular diseases. Activated intracellular RAS may be involved in the development of proliferative diabetic retinopathy. Vitreous levels of angiotensin II19 and of renin30 are elevated in patients with diabetic retinopathy and angiotensin II appears to have angiogenic activity, stimulating vessel growth, as shown in a rabbit model of cornea neovascularisation.26 Elevated levels of angiotensin II also have been found in an oxygen induced model of proliferative retinopathy in the kitten.18 The present paper of Wagner et al supports their earlier conclusion that the elevated vitreous levels of prorenin in diabetic patients are the result of increased synthesis in the retina,21,23 because expression of renin mRNA has been found in the retina.

In the pathogenesis of glaucoma, angiotensin induced vascular tone has been implicated as a pathogenic mechanism in glaucomatous cupping and in damage to the optic nerve.27,28 Regulation of aqueous outflow, and hence intraocular pressure (IOP), occurs in or near the ciliary body and the iris. The evidence for the presence of RAS components necessary for the generation of angiotensin II in this region is suggestive of a local ocular RAS also involved in regulation of IOP. The finding that corneal application of renin inhibitors,29,31 and of an ACE inhibitor,32 lowers IOP supports such a function. Angiotensin II contracts isolated dog saphenous vein via synthesis of cyclo- oxygenase products by acting on specific receptors.15,33

The published data do not distinguish whether activated RAS in the eye is a cause or an effect of the investigated eye diseases. Logically, treatment with enzyme inhibitors, possessing sufficient lipid solubility to cross the blood ocular barriers, seems indicated in prophylaxis or therapy. As already mentioned short term single dose studies of renin inhibitors30 and of an ACE inhibitor,31 applied as eyedrops in healthy volunteers, showed a decrease in the IOP. Unfortunately, animal models, mimicking proliferative retinopathy and glaucomatous damage to the retina, to evaluate the safety and efficacy of chronic administration of therapeutic agents, have not been successful. Whether successful intervention with enzyme inhibitors in the RAS in the eyes of patients suffering from diabetic retinopathy or glaucoma will depend on future clinical trials.

The possibility of undesired side effects, based on the presence of RAS in the neural retina has already been suggested. If the peptide angiotensin II takes the role of transmitter or modulator in retinal neurophysiology, then inhibition of its production might cause disturbance of retinal neuronal function.13


23 Deinum J, Derks FHM, Danser AHJ, Schalekamp MADH. Identification and quantification of renin and prorenin in the bovine eye. Endocrinology 1990; 126: 1673-82.


The renin-angiotensin system in the human eye.

N J Van Haeringen

*Br J Ophthalmol* 1996 80: 99-100
doi: 10.1136/bjo.80.2.99

Updated information and services can be found at: http://bjo.bmj.com/content/80/2/99.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/